Novel drugs to relieve and repair tissue damage caused by osteoarthritis.
BRIM Biotechnology is developing novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRM521’s unique mechanism of action promotes joint cartilage regeneration and relieves pain.
Osteoarthritis is the most common form of arthritis worldwide. It occurs when the cartilage cushioning the end of your bones wears down. Cartilage is a tissue that allows smooth joint movement. In life, our joints experience low level damage which is repaired naturally. However, sometimes cartilage breaks down and bones can rub, resulting in pain, stiffness, grating, loss of flexibility, swelling, and bone spurs. Although this results from natural wear & tear, certain factors increase risk, including joint overuse post-injury, ageing, obesity, being female, gout, or a family history of this condition. With no current cure, osteoarthritis treatment consists largely of lifestyle changes that reduce risk and manage symptoms.
Potential first-in-class injectable treatment for Osteoarthritis
BRM521 is a PEDF-derived Short Peptide (PDSP), which is a new drug candidate for osteoarthritis. Its active pharmaceutical ingredient (API) is the same as BRM421, with a different formulation. The final drug product will be an intra-articular injectable, as a first-in-class new drug.
BRM521’s neurotrophic properties induce cartilage proliferation and the differentiation of mesenchymal stem cells, promoting cartilage regeneration, repairing damaged articular cartilage, and relieving symptoms of pain.
Pre-clinical data indicate that BRM521 has the potential to offer patients therapeutic advantage over existing treatments. Phase I clinical trials for BRM521 are on track to start in Q1 2023.